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bjectives Our purpose was to evaluate percutaneous coronary intervention (PCI) attempt rates in
atients with class I indications for coronary artery bypass graft (CABG) surgery after the introduc-
ion of drug-eluting stents (DES).
ackground In patients with severe, multivessel coronary disease, CABG has historically been rec-
mmended over PCI. Practice guidelines for CABG were last updated before the emergence of data
n DES efﬁcacy.
ethods We analyzed 265,028 procedures from the NCDR (National Cardiovascular Data Registry)
eeting American College of Cardiology/American Heart Association class I indications for surgical
evascularization. Temporal trends in PCI attempt rates were analyzed during 3 consecutive time
eriods: pre-DES (before April 1, 2003), DES diffusion (April 1, 2003 to December 31, 2004), and DES
January 1, 2005 to September 30, 2006).
esults The attempted rate of PCI in patients with class I indications for CABG increased over the 3
ime periods (pre-DES: 29.4%, DES diffusion: 33.4%, and DES era: 34.7%, p  0.001). In a hierarchical
ultivariable logistic model adjusting for patient and PCI site characteristics, PCI attempts were
ore likely in the DES compared with pre-DES era (odds ratio: 1.44, 95% conﬁdence interval: 1.40 to
.48) and the DES diffusion era (odds ratio: 1.20, 95% conﬁdence interval: 1.17 to 1.23). PCI attempt
ates increased in all 3 time periods, although the average rate of increase during the DES era was
.6% per quarter compared with 0.3% per quarter for both the DES diffusion and the pre-DES eras
p  0.03).
onclusions DES use in clinical practice was associated with a signiﬁcant overall increase in PCI to
reat patients with class I indications for CABG. Long-term follow-up of this cohort of patients is
arranted. (J Am Coll Cardiol Intv 2009;2:614–21) © 2009 by the American College of Cardiology
oundation
rom the *Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri; and the †Denver Veteran’s
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615oronary artery bypass grafting (CABG) has been the
tandard revascularization strategy for patients with left
ain and severe multivessel coronary artery disease (CAD)
1,2). Multivessel percutaneous coronary intervention (PCI)
ith bare-metal stents (BMS) has achieved similar freedom
rom mortality and myocardial infarction (MI) as CABG
ut at a significant cost of repeat revascularization (3). The
ntroduction of drug-eluting stents (DES) dramatically
mproved vessel patency compared with BMS (4,5) and may
See page 622
ave impacted physician judgment on the appropriateness of
CI in patients with multivessel disease. Recent data suggest
hat multivessel PCI with DES has comparable survival to
ABG at long-term follow-up (6). However, discordant data
ave also been published from the New York State CABG and
CI databases demonstrating improved survival among those
ith multivessel CAD treated with CABG compared with
ES-PCI (7).
There has been little data to evaluate whether the intro-
uction of DES has influenced clinical practice with regard to
he use of PCI rather than CABG surgery among patients
ith indications for CABG. Thus, we examined data from the
CDR (National Cardiovascular Data Registry) to determine
hether the introduction and adoption of DES in clinical
ractice has led to greater use of PCI among patients with class
indications for CABG.
ethods
tudy population and deﬁnitions. A description of the
CDR has been previously published (8,9). Analysis was
imited to centers reporting data on both diagnostic coro-
ary angiography and PCI procedures from January 1, 2001
o September 30, 2006. Centers not reporting both proce-
ures or changing reporting methods over time were excluded.
Eligible patients had 1 of the following American
ollege of Cardiology/American Heart Association class I
ndications (2) for isolated CABG surgery: 1) left main
tenosis50%; 2) left main equivalent disease (proximal left
nterior descending coronary artery [LAD] and left circum-
ex stenosis 70%); 3) 3-vessel disease; 4) proximal LAD
50% and left ventricular ejection fraction 50%; 5) 2- or
-vessel disease and left ventricular ejection fraction 50%;
r 6) 2-vessel disease including proximal LAD with either
ngina or demonstrable ischemia on stress testing (2).
atients having emergency or salvage indications for PCI or
ABG, history of CABG or PCI, an indication for cath-
terization of aortic or mitral valve disease, ST-segment
levation MI, or prior cardiac transplant were excluded.
Patients were classified a priori into 3 separate time
eriods according to DES availability and prior data sug-
esting an increased usage rate until the year 2005 (10): N) pre-DES era (before April 1, 2003, date of sirolimus-eluting
tent approval); 2) DES diffusion era (April 1, 2003 to
ecember 31, 2004, date 75% DES use achieved); and 3)
ES era (January 1, 2005 to September 30, 2006). The last
uarter of 2006 was not included as the first data on late
tent thrombosis associated with DES use were presented at
he World Congress of Cardiology in Barcelona during this
ime (11). These dates were then re-evaluated by examining
articipating centers that submitted uninterrupted data to
he NCDR in at least 2 of the 3 time periods for all and
mong patients with class I indications for CABG.
tatistical analysis. Baseline characteristics were compared
n each pre-specified time period using a chi-square test for
ategorical variables and a 1-way analysis of variance test for
ontinuous variables. Average quarterly DES utilization
ates were calculated for all patients and patients with class
indications for CABG, with results graphically displayed
o validate the a priori time grouping. Unadjusted slope
omparisons of PCI attempt rates over time between the 3
eriods were performed using a
eneralized linear model weight-
ng the quarterly mean PCI rates
t each site in patients with class
indications. To further evaluate
CI use during each time pe-
iod, a hierarchical multivariable
ogistic regression model was
enerated using hospital site as
he second order. Covariates in-
luded age, sex, race, body mass
ndex, acute coronary syndrome,
istory of congestive heart fail-
re, New York Heart Associa-
ion functional class, ejection frac-
ion, hypercholesterolemia, left
ain stenosis 50%, number of diseased vessels, and absence
f diabetes, renal failure, cerebrovascular disease, peripheral
ascular disease, prior MI, hypertension, and tobacco use. An
dditional time covariate was not included due to collinearity
ith the 3 specified time periods (variance inflation factor 
.9 and highly correlated eigenvalues0.5). Variables in the
odel determined to be statistically significant are displayed
n a forest plot. Further analysis was performed to determine
he effect of DES utilization on PCI attempt rates in the
ES era by calculating the quarterly DES utilization rate
or all PCI procedures at each site. A hierarchical multiva-
iable logistic model using the same covariates as above was
erformed with quarterly DES utilization rate as the main
ffect of interest. From this model, an adjusted PCI attempt
ate was calculated across deciles of DES utilization rates
nd displayed using a skeletal box and whisker plot. Statis-
ical significance was defined as p  0.05. Analyses were
erformed using SAS version 9.1 (SAS Institute, Cary,
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
DES  drug-eluting stent(s)
LAD  left anterior
descending coronary artery
MI  myocardial infarction
PCI  percutaneous
coronary interventionorth Carolina).
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616esults
ES utilization rates for the entire NCDR PCI population
N 1.06 million) and PCI patients with class I indications
or CABG (n  265,028) are shown in Figures 1A and 1B,
espectively. Among all patients undergoing PCI, use of
ES increased steadily to approximately 84% in 2005 (Fig.
A). In patients with class I indications for CABG, DES
tilization also increased and reached a plateau of 88%
uring the DES era.
Baseline clinical characteristics, class I indications for
ABG, and medical center characteristics are shown in
able 1. Among patients with class I indications for CABG
uring the study period, 87,139 (33%) underwent PCI.
here were 299 centers included in the analysis, although all
ere not equally represented during all 3 time periods (216
re-DES, 292 DES diffusion, and 299 DES era). There
ere no statistically significant differences in in-hospital
vents including death and vascular complications.
Since the adoption of DES, there was a decrement in
atients identified as having a class I indication for CABG
12.4% in the pre-DES vs. 11.7% in the DES diffusion and
0.7% in the DES era, p 0.001) and a statistically significant
ecrease in the rate of in-hospital CABG (33.0% vs. 30.1%
nd 30.7%, respectively, p  0.001). However, PCI attempt
ates increased steadily over time among patients with any class
indication (29.4% vs. 33.4% and 34.7%, respectively, p 
.001) (Fig. 2), although the average rate of increase during the
ES era was 2-fold greater (0.6% per quarter) than the DES
iffusion and the pre-DES eras (0.3% per quarter for both, p
.03). Results of the hierarchical multivariable logistic model
ontrolling for hospital site are displayed in Figure 3. After
djustment, PCI attempt rates in patients with class I indica-
Figure 1. DES Use in PCIs
The proportion of patients undergoing percutaneous coronary interventions (PCIs)
diffusion, and DES era in the entire National Cardiovascular Data Registry populati
ing (CABG) (B). DES use increased to a maximum of 88% in all PCIs during the second qions for CABG were greatest in the DES compared with
re-DES era (odds ratio: 1.44, 95% confidence interval: 1.40 to
.48) and the DES diffusion era (odds ratio: 1.20, 95%
onfidence interval: 1.17 to 1.23).
Figure 3 demonstrates the relative odds of PCI attempt rates
n subgroups of clinical interest. The absence of presumed high
isk clinical demographics including diabetes mellitus, renal
ailure, cerebral vascular disease, peripheral vascular disease,
I, hypertension, and tobacco use were associated with
ncreased odds of attempted PCI. Increased likelihood of
ttempted PCI was also evident in younger patients, women,
on-Caucasians, and patients with acute coronary syndromes,
igher ejection fraction, and less diffuse disease.
PCI attempt rates among patients with selected class I
ndications by time period are shown in Table 2. For each
ndication, PCI was more likely to be attempted after than
efore the adoption of DES in clinical practice.
Although the rate of DES use during the DES era
ppeared to be steady, intracenter and intercenter variability
n PCI attempt rates and DES utilization was apparent.
igure 4 displays the relationship between PCI attempt rate
nd DES use by site during the DES era. On average,
enters using more DES were more likely to attempt PCI in
atients with class I CABG indications.
iscussion
ver a 6-year period from 2001 to 2006, we found that use
f PCI as the initial form of revascularization among
atients with a class I indication for CABG increased in a
ashion that was temporally related to the introduction and
doption of DES into U.S. practice. This increase was seen
cross all categories of patients regardless of clinical char-
drug-eluting stents (DES) by quarter from 2001 to 2006 during the pre-DES, DES
and limited to patients with class I indications for coronary artery bypass graft-with
on (A)uarter of 2005. Deﬁnitions of each time interval as in Table 1.
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617cteristics, indications for surgical revascularization, comor-
idities, or surgical risk score. Similarly, there was a corre-
ponding decrease in in-hospital referral to CABG surgery.
lthough an increase in PCI attempt rates was observed in
Table 1. Clinical Characteristics, Class I Indications for CABG, and Medica
Pre-DES
Before April 1, 2003
(N  67,316)
Age*, yrs 67.0 11.8
Men*, % 67.8
Caucasian*, % 89.8
Acute coronary syndrome*, % 59.6
Diabetes mellitus*, % 34.8
Renal failure*, % 5.8
Cerebrovascular disease, % 13.5
Peripheral vascular disease*, % 15.8
Prior myocardial infarction*, % 20.5
Current congestive heart failure*, % 14.4
Chronic lung disease*, % 16.9
Hypertension*, % 70.8
Current smoking*, % 23.8
Dyslipidemia*, % 59.3
Height*, cm 171.0 10.8
Weight*, kg 85.2 19.7
Body mass index*, kg/m2 29.3 12.7
Ejection fraction*, % 48.4 14.4
Diseased vessels, %
1 5.3
2 32.4
3 62.2
Class I CABG indications*, %
Left main 50% 15.8
Left main equivalent 24.7
3-vessel disease 50% 32.6
Proximal LAD 50% and LVEF 50%* 10.6
2 or 3 vessels 50% and LVEF 50%* 9.8
Angina, positive stress test, and 2 vessels with
proximal LAD 50%*
6.5
Center characteristics
Diagnostic catheterizations/year, n 1,889.7 1,270.5
PCI/year, n 787.3 605.2
400 PCI/year, % 71.1
Onsite CABG, % 91.7
Hospital type, %
Government 1.8
Community 91.7
University 6.4
In-hospital events, %
Death 1.8
Vascular complications 1.4
In-hospital CABG 33.0
*p 0.001, 3-group comparison.
CABG coronary artery bypass grafting; DES drug-eluting stent(s); LAD left anterior descenll pertinent subgroups, including patients with 3-vessel rAD, PCI was not performed indiscriminately, as evi-
enced by a higher likelihood for PCI in subjects with lower
isk (e.g., 1- or 2-vessel disease) than higher-risk class I
ndications for CABG (i.e., left main or 3-vessel CAD). In
ter Characteristics
DES Diffusion
1, 2003 to December 31, 2004
(N  97,402)
DES
January 1, 2005 to September 30, 2006
(N  100,310)
67.1 11.8 66.4 11.8
68.0 68.6
88.8 86.6
57.5 59.4
35.5 36.7
6.8 6.9
13.5 13.4
14.7 13.9
18.9 17.4
13.9 15.1
17.3 17.8
74.0 75.7
23.5 25.2
63.9 67.7
171.0 10.8 171.3 11.1
85.5 20.2 86.2 20.5
29.3 10.3 29.3 6.3
48.5 14.0 48.3 13.4
5.2 5.3
32.4 32.7
62.4 62.0
16.5 17.3
24.6 24.7
32.6 31.5
10.2 10.4
9.2 8.7
6.9 7.4
1,841.9 1,290.0 1,834.7 1,284.5
798.9 642.8 795.0 639.8
71.2 70.9
89.0 89.0
1.4 1.3
91.4 91.6
7.2 7.0
1.6 1.6
1.4 1.2
30.1 30.7
EF left ventricular ejection fraction; PCI percutaneous coronary intervention.l Cen
Aprilisk-adjusted models accounting for site, PCI attempt rate
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618as independently associated with the DES era among
atients with class I indications for CABG surgery.
Two earlier studies in more select populations demon-
trated a similar association between the introduction of
ES and the increased use of PCI in patients with
ndications for surgical revascularization. A previous study
rom the NCDR (12) showed that among 32,563 patients
ith unprotected severe left main artery disease, the use of
CI increased from 17.0% in 2002 to 21.9% in 2004—the
ear immediately after DES approval (p  0.0001). At the
ame time, use of CABG in these patients decreased from
3.0% to 78.1% (p  0.0001). Similar to our findings, these
rends were seen among selected clinical subgroups, includ-
ng elective procedures. In another previous study (13),
nvestigators with the CRUSADE (Changes in Patterns of
oronary Revascularization Strategies for Patients With
cute Coronary Syndromes) quality improvement initiative
ound that among 25,068 patients presenting with non–ST-
egment acute coronary syndromes and 3-vessel disease, the
ate of PCI increased (51.1% to 60.1%), medical manage-
ent remained relatively constant (27.8% to 25.5%), and
he use of CABG decreased (48.9% to 39.9%). Our findings
dd to these studies in 2 ways. First, our cohort consisted of
ll patients with American College of Cardiology/American
eart Association class I indications for CABG and,
herefore, included a much broader population of patients.
econd, the study cohort also included large numbers of
atients who presented with and without acute coronary
yndromes (59% and 41%, respectively), demonstrating a
Figure 2. PCI Attempts in Patients With Class I Indications for CABG
The proportion of patients with class I CABG indications undergoing attempte
era. *p  0.001 versus pre-DES era. The quarterly slope of increase was 2-fold
DES era. Abbreviations as in Figure 1. Deﬁnitions of each time interval as in Taimilar association between increased PCI use and availabil- ity of DES regardless of presentation to the catheterization
aboratory.
Early clinical trials demonstrated that CABG was pre-
erred over medical therapy in patients with left main or
evere multivessel CAD (1). Subsequent clinical trials dem-
nstrated that multivessel PCI with BMS achieves similar
reedom from mortality and MI as CABG, but at a cost of
xcess repeat revascularization (3). In a separate observa-
ional study, Park et al. (6) found that patients who had
ultivessel PCI with DES had comparable mortality at 3
ears compared with CABG patients. These investigators
lso found that rates of repeat revascularization were higher
n those who underwent PCI with DES than CABG. In
ontrast, using data from the New York State CABG and
CI registries Hannan et al. (7) reported that subjects with
ultivessel CAD who underwent DES-PCI had decreased
urvival at intermediate follow-up (18 months) compared
ith that seen with CABG. The absolute difference in
ortality was 2.7%. Whether this survival difference persists
eyond 18 months is not known. Moreover, although the
uthors attempted to adjust for selection bias using multi-
ariable modeling and propensity analysis it is likely that at
east some of the observed difference is related to unmea-
ured confounding (14). It should be noted that both of
hese studies were observational in design and, therefore, do
ot provide definitive evidence of the superiority of one
trategy over the other.
The attractiveness of using DES-PCI over CABG may
tem from risks of perioperative mortality and morbidity,
by quarter from 2001 to 2006 during the pre-DES, DES diffusion, and DES
r in the DES than the DES diffusion and pre-DES eras. *p  0.03 versus pre-d PCI
greatencluding risk of stroke, neurocognitive decline, sternal
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619ound infection, and bleeding in patients undergoing
ABG (15). Also, in certain subgroups, PCI with BMS
ppears to be less expensive than CABG even at long-term
ollow-up (16). At the same time, DES-PCI reduces
n-stent restenosis and repeat revascularization in a variety
f clinical settings (17–21), potentially improving the risk-
enefit ratio of multivessel PCI compared with CABG in
atients whose clinical characteristics place them at higher
isk for surgical complications.
Many questions remain on the efficacy of DES compared
ith CABG in this population, including rates of stent
Figure 3. Hierarchical Multivariable Logistic Regression Model
Predictors of PCI in patients with class I coronary artery bypass grafting indica
 acute coronary syndromes; CVD  cardiovascular disease; Dx  diseased; L
other abbreviations as in Table 1.
Table 2. PCI Attempts by Individual Class I Indicatio
Pre-DE
(N  67,
Left main stenosis 50% 609 (5
Left main equivalent 3,940 (2
3-vessel disease 6,076 (2
Proximal LAD 50% and LVEF 50% 3,681 (5
2- or 3-vessel disease and LVEF 50% 3,277 (4
Class I indication with abnormal stress test 2,241 (5
Data are n (%).Abbreviations as in Table 1.hrombosis and durability of vessel patency. A number of
egistries have demonstrated that DES-PCI in patients with
nprotected left main or multivessel disease is not only
easible but may improve outcomes over BMS (22,23). It
as also been shown that prior PCI is associated with an
ncreased hazard for future CABG (24). Furthermore, the
merican College of Cardiology/American Heart Associa-
ion/Society for Cardiovascular Angiography and Interven-
ions guideline update for PCI leaves much to the discretion
f the operator and provides only an explicit recommenda-
ion against unprotected left main stenting (25). Neverthe-
Solid circles represent odds ratios; lines are 95% conﬁdence intervals. ACS
eft main; MI  myocardial infarction; PVD  peripheral vascular disease;
ABG
DES Diffusion
(N  97,402)
DES
(N  100,310) p Value
1,131 (7.0) 1,134 (6.5) 0.001
6,923 (28.9) 7,637 (30.9) 0.001
10,242 (32.3) 10,497 (33.2) 0.001
5,435 (54.8) 6,044 (57.8) 0.001
4,875 (54.2) 4,953 (56.8) 0.001
3,885 (57.9) 4,559 (61.5) 0.001tions.
M  ln for C
S
316)
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620ess, randomized controlled trials comparing multivessel
ES-PCI with CABG are needed to determine longitudi-
al outcomes including death, MI, and revascularization.
Reports of late and very late stent thrombosis and
oncomitant adverse clinical outcomes associated with DES
26) raise concerns that multivessel or left main stenting
ith DES may augment a very low but real risk of
atastrophic events. In addition, risk factors for late stent
hrombosis associated with DES have only recently
merged (27,28). Multivessel or left main stenting may
ntroduce other factors that increase risk, such as off-label
se of DES in small vessels or more complex lesions (29).
hese concerns are compounded by a report indicating a
izable number (14%) of patients who received DES during
rimary PCI discontinued thienopyridine therapy within 30
ays and had a 10-fold increase in 1-year mortality (30).
lthough the clinical consequences and long-term implica-
ions of this significant shift toward PCI among patients
ith class I CABG indications have yet to be determined,
ur findings should emphasize that the widespread adoption
f novel device technology platforms such as DES can occur
n populations not represented in the initial clinical trials
valuating these technologies.
There are a number of limitations to our study. First, we
Figure 4. Quarterly PCI Attempts by Decile of DES Utilization
A hierarchical multivariable logistic regression model with quarterly DES utiliza
rate of PCI attempted during the DES era at each hospital site (p  0.036). Th
artery bypass grafting. The X-axis is the mean quarterly DES utilization rate byannot establish a causal relationship between the availabil- hty of DES and the observed revascularization trends. Other
dvances in coronary interventional practice and technology
s well as adjunctive medical therapy may have contributed
o this trend, although none are as prominent in the time
eriod studied as the introduction of DES. Second, the
CDR does not record data on lesion anatomy or the role
f patient preferences and procedure refusals, all of which
ay have impacted revascularization decisions. Third, we
ere unable to directly compare PCI and CABG rates
mong patients with class I indications because the NCDR
aptures data at diagnostic catheterization only for in-
ospital referrals for CABG. Thus, a sizable proportion of
atients may have returned for elective CABG. Fourth, we
ecognize that our unadjusted reported increase in use of
ES in patients with class I indications for CABG at first
lance seems modest. However, this actually represents a
elative 18% increase in PCI, translating into several thou-
and patients undergoing attempted PCI. Extrapolated to
ll centers performing PCI in the U.S., we believe this
ncrease is not only statistically significant but clinically
mportant. Finally, we were unable to determine the impact
f changes in revascularization strategy on long-term clini-
al outcomes, complications, or subsequent hospitalizations,
ecause the NCDR is limited to periprocedural or in-
ate as the main effect of interest was developed to determine the adjusted
is is the PCI attempt rate in patients with a class I indication for coronary
r. Abbreviations as in Figure 1.tion r
e Y-axospital events.
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621onclusions
he introduction and widespread adoption of DES was
ssociated with a significant increase in the use of PCI to
reat patients with severe multivessel CAD with class I
ndications for CABG. Long-term follow-up from random-
zed controlled trials among such patients is needed to
nderstand the implications of this trend.
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